Omeros

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Omeros and other ETFs, options, and stocks.

About OMER

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. 

CEO
Gregory A. Demopulos
CEOGregory A. Demopulos
Employees
175
Employees175
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
1994
Founded1994
Employees
175
Employees175

OMER Key Statistics

Market cap
627.13M
Market cap627.13M
Price-Earnings ratio
10.13
Price-Earnings ratio10.13
Dividend yield
Dividend yield
Average volume
3.24M
Average volume3.24M
High today
$9.38
High today$9.38
Low today
$7.35
Low today$7.35
Open price
$7.50
Open price$7.50
Volume
10.92M
Volume10.92M
52 Week high
$17.65
52 Week high$17.65
52 Week low
$2.95
52 Week low$2.95

Stock Snapshot

The current Omeros(OMER) stock price is $8.60, with a market capitalization of 627.13M. The stock trades at a price-to-earnings (P/E) ratio of 10.13.

As of 2026-06-28, Omeros(OMER) stock has fluctuated between $7.35 and $9.38. The current price stands at $8.60, placing the stock +17.0% above today's low and -8.4% off the high.

The Omeros(OMER)'s current trading volume is 10.92M, compared to an average daily volume of 3.24M.

During the past year, Omeros(OMER) stock moved between $2.95 at its lowest and $17.65 at its peak.

During the past year, Omeros(OMER) stock moved between $2.95 at its lowest and $17.65 at its peak.

OMER News

Benzinga 2d
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide

• Omeros stock is feeling bearish pressure. Why is OMER stock dropping? The company was seeking approval for Yartemlea (narsoplimab) for adults and children fr...

FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide
Seeking Alpha 2d
Omeros drops as transplant therapy faces EU hurdle

Shares of Omeros (OMER) fell ~25% in the premarket on Friday after an expert panel of the EU drug regulator, the European Medicines Agency, declined to endorse...

Omeros drops as transplant therapy faces EU hurdle
TipRanks 2d
Omeros announces CHMP adopts negative opinion on MAA for narsoplimab

Omeros (OMER) Corporation announced an update on the review by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the compan...

People also own

Based on the portfolios of people who own OMER. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.